Company

Immuthera

Biotechnology Research Has Granted Poltreg a New Patent Titled “Method for Ex Vivo Expansion of Regulatory T Cells.” 1 employees

Employees: 1
Contacts: 1
Emails: 1

immuthera.bio LinkedIn

Immuthera Overview

Headquarters: Has Granted Poltreg a New Patent Titled “Method for Ex Vivo Expansion of Regulatory T Cells.”
Website: immuthera.bio
Industry: Biotechnology Research
Employees: 1
Funding: ,
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

AvenCell

About Immuthera

Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG’s Research and Development capabilities along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States.